6 I kontrollerede monoterapistudier med vildagliptin var den samlede hyppighed af udtræden på grund af bivirkninger ikke større for de patienter, der modtog behandling med vildagliptin- doser på 100 mg daglig (0, 3%) end for de patienter, der fik placebo (0, 6%) eller sammenligningsstoffer (0, 5%).
6 In addition, in controlled monotherapy trials with vildagliptin the overall incidence of withdrawals due to adverse reactions was no greater for patients treated with vildagliptin at doses of 100 mg daily (0.3%) than for placebo (0.6%) or comparators (0.5%).